Table 3.
Characteristics of PD patients with or without dyskinesia.
| Dyskinesia | With (n = 25) | Without (n = 141) | t/χ2 | P value |
|---|---|---|---|---|
| Sex (male/female) | 16/9 | 73/68 | 1.227 | 0.259 |
| Age (mean ± SD, y) | 65.92 ± 10.08 | 65.84 ± 8.97 | 0.042 | 0.966 |
| Onset age (mean ± SD, y) | 55.92 ± 11.18 | 61.74 ± 9.46 | 2.755 | 0.007 |
| Disease duration (median, quartile, y) | 9 (6∼13.5) | 3 (2∼5) | 6.113 | <0.001 |
| Clinical phenotypes (n, %) | 5.529 | 0.019 | ||
| Tremor | 8 (32.00) | 81 (57.45) | ||
| Bradykinesia-rigidity | 17 (68.00) | 60 (42.55) | ||
| Modified Hoehn–Yahr stages (median, quartile) | 3 (2.75∼3.5) | 2 (1.5∼2.5) | 5.569 | <0.001 |
| UPDRS III scores (mean ± SD) | 33.08 ± 15.18 | 20.26 ± 10.03 | 4.065 | <0.001 |
| Daily levodopa dosage (mg, median, quartile) | 500 (375∼750) | 375 (375∼500) | 2.175 | 0.030 |
| LEDD (mg/d, mean ± SD) | 796.15 ± 544.42 | 395.22 ± 314.25 | 4.723 | <0.001 |
| L-dopa duration (mean ± SD, y) | 7.40 ± 3.81 | 2.15 ± 3.04 | 5.481 | <0.001 |
| Medications (n%) | ||||
| Levodopa-benserazide | 24 (96.00) | 111 (78.72) | 4.173 | 0.041 |
| Levodopa-carbidopa | 7 (28.00) | 4 (2.84) | 21.731 | <0.001 |
| Dopamine agonist | 19 (76.00) | 73 (51.77) | 5.405 | 0.025 |
| MAO-B inhibitor | 9 (36.00) | 35 (24.82) | 1.365 | 0.243 |
| COMT inhibitor | 5 (20.00) | 4 (2.84) | 12.199 | <0.001 |
| Anticholinergic | 6 (24.00) | 24 (17.02) | 0.698 | 0.403 |
| Amantadine | 2 (8.00) | 10 (7.02) | 0.026 | 0.087 |
Abbreviations: SD, standard deviation; UPDRS: unified Parkinson disease rating scale; LEDD: levodopa equivalent daily dose; Mao: monoamine oxidase; and COMT: catechol-o-methyltransferase.